Kura Oncology Financial Ratios
NASDAQ: KURAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
10.60+0.08 (+0.76%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kura Oncology ratio analysis
Kura Oncology earned a net margin of -412.9% in FY 2025, down from -322.9% a year earlier. Return on equity reached -160.0%, meaning Kura Oncology generated -1.60 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.06 versus 0.02 the year before, and the current ratio was 6.06.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Kura Oncology financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 13.43 | 13.96 | — | — | — | — | — | — | — | — |
| Price / book | 5.20 | 1.82 | 2.65 | 1.98 | 1.83 | 2.84 | 2.60 | 3.31 | 4.45 | 1.94 |
| Operating margin | -449.9% | -358.5% | — | — | — | — | — | — | — | — |
| Net margin | -412.9% | -322.9% | — | — | — | — | — | — | — | — |
| Free cash flow margin | -104.8% | 248.4% | — | — | — | — | — | — | — | — |
| Return on equity (ROE) | -160.0% | -42.1% | -38.4% | -32.3% | -25.8% | -14.7% | -28.9% | -37.5% | -44.4% | -48.5% |
| Return on assets (ROA) | -37.7% | -22.9% | -34.0% | -29.8% | -24.4% | -13.8% | -26.1% | -33.1% | -37.0% | -39.5% |
| Debt / equity | 0.06 | 0.02 | 0.02 | 0.02 | — | 0.01 | 0.03 | 0.05 | 0.09 | 0.13 |
| Current ratio | 6.06 | 9.46 | 12.26 | 18.56 | 23.26 | 24.49 | 15.39 | 13.31 | 9.43 | 12.62 |
| Revenue growth | 25.2% | — | — | — | — | — | — | — | — | — |